Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?

INTRODUCTION: In hormone receptor-positive metastatic breast cancer without human epidermal growth factor receptor 2 overexpression (HR+/HER2−), a significant progression-free survival benefit has been obtained with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in the first-line treatment. We mai...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Burcu Gulbagci, Ayşe Demirci, Abdüssamet Çelebi, Sedat Tarık Fırat, Ivo Gökmen, Irem Uğurlu, Huri Tilla Ilçe, Emre Çakır, Ilhan Hacıbekiroğlu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Via Medica 2026-02-01
coleção:	Oncology in Clinical Practice
Assuntos:	cyclin-dependent kinase neutropenia metastatic breast cancer palbociclib ribociclib
Acesso em linha:	https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/101970
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!